Tango Therapeutics TNGX Business Segments
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| Research And Development Expense by Business | ||||
| Discovery Direct Program Expenses-RD | $10.17M-58.4% | $24.44M+4.3% | $23.43M-18.6% | |
| Facilities And Other Related Expenses-RD | $20.46M+8.4% | $18.88M+7.5% | $17.56M+24.1% | |
| Personnel-Related Expenses-RD | $51.47M0.0% | $51.46M+33.8% | $38.47M+36.5% | |
| TNG260Direct Program Expenses-RD | $6.28M-33.1% | $9.38M+14.8% | $8.17M+66.6% | |
| TNG456Direct Program Expenses-RD | $6.56M+44.7% | $4.53M— | $0— | |
| TNG908Direct Program Expenses-RD | $5.03M-63.0% | $13.59M+25.2% | $10.85M-15.3% | |
| TNG961Direct Program Expenses-RD | $5.68M— | $0— | $0— | |
| Vopimetostat Direct Program Expenses-RD | $26.52M— | —— | $10.16M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Tango Therapeutics break its business down?
- Tango Therapeutics (TNGX) reports research and development expense by business across 8 parts — Discovery Direct Program Expenses-RD, Facilities And Other Related Expenses-RD, Personnel-Related Expenses-RD, TNG260Direct Program Expenses-RD and TNG456Direct Program Expenses-RD. Each is extracted from the segment footnotes and tracked over time.
- Where does Tango Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Tango Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.